Last Updated: May 11, 2026

Litigation Details for Largan Precision Co., Ltd. v. Samsung Electronics Co., Ltd. (S.D. Cal. 2013)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Largan Precision Co., Ltd. v. Samsung Electronics Co., Ltd.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Largan Precision Co., Ltd. v. Samsung Electronics Co., Ltd.: 3:13-cv-02740

Last updated: March 31, 2026

Case Overview

Largan Precision Co., Ltd. filed suit against Samsung Electronics Co., Ltd., on April 30, 2013, in the United States District Court for the Northern District of California. The case (No. 3:13-cv-02740) centered on claims of patent infringement related to camera lens technology.

Claim Details and Allegations

Largan asserted that Samsung's camera modules employed in multiple Galaxy device models infringed upon two patents:

  1. U.S. Patent No. 8,006,214 – Covering a liquid lens with specific focusing mechanisms.

  2. U.S. Patent No. 8,201,842 – Covering a multi-layered lens structure with particular manufacturing methods.

The core allegations claim Samsung's use of these technologies violates Largan's patent rights, potentially impacting large volumes of smartphones.

Court Proceedings and Decisions

Procedural Timeline

  • April 2013: Complaint filed.
  • October 2013: Samsung filed a motion to dismiss or stay, citing inter partes reviews (IPRs) initiated at the Patent Trial and Appeal Board (PTAB).
  • March 2014: The court denies Samsung's motion, allowing the case to proceed.
  • 2014–2016: Discovery phase, during which both parties exchanged technical information and conducted depositions.
  • October 2016: The case is scheduled for trial.

Patent Office Inter Partes Reviews

Samsung petitioned for IPRs for both patents, arguing invalidity. Both proceedings resulted in partial invalidation:

  • The PTAB found some claims of the '214 patent partially unpatentable but upheld others.
  • The '842 patent's claims faced similar, mixed rulings.

Despite these, the district court's initial findings affirmed the validity of the patents’ core claims.

Settlement and Resolution

In 2017, the parties settled the matter before the case could proceed to trial. The terms were not publicly disclosed, but Samsung issued a licensing agreement to Largan, settling all patent infringement claims.

Key Legal Issues

  • Patent Validity: PTAB rulings on partial invalidity influenced the case but did not result in a final court ruling on patent validity.
  • Infringement: The district court maintained that Samsung's products infringed on the valid claims of Largan's patents.
  • Inter Partes Review Impact: The IPR proceedings affected the litigation's strategic approach, but did not by themselves resolve infringement claims.

Market and Industry Impact

The case underscored the importance of lens technology patents amid rising smartphone photography capabilities. It highlighted the ongoing patent conflicts between Largan, a dominant lens supplier, and major smartphone manufacturers like Samsung.

Samsung's response involved initiating IPRs, a common strategy to challenge patent validity. The resolution via settlement reflects a broader trend where patent disputes are often resolved through licensing agreements rather than court judgments.

Financial and Strategic Ramifications

  • Samsung agreed to license Largan's patents, likely involving significant royalty payments, given Largan's market dominance.
  • The case reinforced Largan's patent portfolio value, especially in a high-growth segment of mobile imaging.
  • The legal proceedings drew industry attention to patent enforcement practices, influencing how manufacturers approach licensing.

Industry and Legal Trends

  • Patent disputes over smartphone camera technologies persist, with companies litigating over lens, sensor, and interface patents.
  • PTAB's IPR process remains a tool for accused infringers to challenge patents, influencing litigation strategies.
  • Settlements are common, as patent owners seek licensing revenue rather than prolonged legal battles.

References

  1. Court docket and case filings for Case No. 3:13-cv-02740, U.S. District Court for the Northern District of California.
  2. PTAB decision documents for IPR proceedings related to patents '214 and '842.
  3. Final settlement press releases from Largan and Samsung, 2017.

Key Takeaways

  • The case exemplifies the merging of patent litigation and IPR procedures in patent enforcement strategies.
  • Settlement reflects a pragmatic resolution, balancing litigation costs and patent valorization.
  • Patent validity challenges at PTAB influence, but do not automatically resolve infringement cases in district court.
  • The case underscores the high value of lens technology patents amid mobile imaging innovation.
  • Industry players continue to leverage patent portfolios as strategic assets in litigation and licensing.

FAQs

1. Did Samsung admit infringement in this case?
No. The case was resolved with a licensing agreement before the court issued a final infringement or validity ruling.

2. What role did IPR proceedings play in this case?
They challenged the patents' validity but did not result in their invalidation, affecting the case's strategic dynamics.

3. Are patent disputes over smartphone camera technology common?
Yes. Patent conflicts over lens, sensor, and image processing technologies are prevalent in the industry.

4. What is the typical resolution for such cases?
Most are settled through licensing agreements or dismissed after invalidity rulings. Litigation is often used to negotiate better licensing terms.

5. How does PTAB's IPR process influence patent enforcement?
It serves as a tool for accused infringers to challenge patents' validity, often prompting settlement or licensing discussions.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.